Tvardi Therapeutics Inc (TVRD)

07:17 AM

Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating - Investing.com

07:17 AM

Jul 13, 2025

Cantor Fitzgerald Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World

Jul 13, 2025

Jul 12, 2025

Tvardi Therapeutics: A Catalyst-Driven Biotech Play with 130% Upside Potential - AInvest

Jul 12, 2025

Jul 11, 2025

Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com

Jul 11, 2025

Jul 11, 2025

Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target - MarketScreener

Jul 11, 2025

Jun 30, 2025

Tvardi Therapeutics, Inc.(NasdaqCM: TVRD) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025

Jun 12, 2025

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga

Jun 12, 2025

Jun 12, 2025

Tvardi Therapeutics up after Piper Sandler starts coverage - TradingView

Jun 12, 2025

Jun 12, 2025

Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - MarketScreener

Jun 12, 2025

Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia

Jun 12, 2025

Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Nigeria

Jun 12, 2025

Jun 09, 2025

Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks

Jun 09, 2025

May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa

May 28, 2025

May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com

May 28, 2025

May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025

May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025

May 27, 2025

Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks

May 27, 2025

May 24, 2025

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail

May 24, 2025

May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa

May 21, 2025

May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com

May 21, 2025

May 21, 2025

Oppenheimer Initiates Tvardi Therapeutics at Outperform With $65 Price Target - marketscreener.com

May 21, 2025

May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com

May 21, 2025

May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India

May 21, 2025

May 20, 2025

Tvardi Therapeutics to Participate in Upcoming Investor Conferences - FinancialContent

May 20, 2025

May 15, 2025

BTIG Initiates Tvardi Therapeutics at Buy With $55 Price Target - marketscreener.com

May 15, 2025

May 15, 2025

BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com

May 15, 2025

May 14, 2025

Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN

May 14, 2025

May 14, 2025

Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter

May 14, 2025

May 13, 2025

Tvardi: Q1 Earnings Snapshot - Huron Daily Tribune

May 13, 2025

May 13, 2025

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire

May 13, 2025

May 09, 2025

Tvardi Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView

May 09, 2025

May 06, 2025

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire

May 06, 2025

May 01, 2025

Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock By Investing.com - Investing.com Canada

May 01, 2025

Apr 30, 2025

Lucid Capital Markets sets $42 target for Tvardi Therapeutics stock - Investing.com

Apr 30, 2025

Apr 23, 2025

Form 8-KCurrent report - ADVFN

Apr 23, 2025

Apr 17, 2025

TVRD stock soars to 52-week high, reaching $19.01 - Investing.com Australia

Apr 17, 2025

Apr 16, 2025

Tvardi Therapeutics, Inc. Rings the Closing Bell - Nasdaq

Apr 16, 2025

Apr 16, 2025

TVRD Stock Price and Chart — NASDAQ:TVRD - TradingView

Apr 16, 2025

Apr 16, 2025

Tvardi Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Apr 16, 2025

Apr 15, 2025

Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz

Apr 15, 2025

Apr 15, 2025

Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks

Apr 15, 2025

Apr 15, 2025

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire

Apr 15, 2025

Apr 15, 2025

Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal

Apr 15, 2025

Apr 14, 2025

Cara Therapeutics (CARA) to Rebrand and Trade as Tvardi Therapeu - GuruFocus

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-for-3 Reverse Stock Split - citybiz

Apr 14, 2025

Apr 14, 2025

Cara Therapeutics Announces 1-For-3 Reverse Stock Split - marketscreener.com

Apr 14, 2025